Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Merus N.V.

Equities

MRUS

NL0011606264

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:21:10 2024-04-25 am EDT 		5-day change 1st Jan Change
42.42 USD +1.08% Intraday chart for Merus N.V. +4.26% +53.44%
Apr. 19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Mar. 28 Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target MT

Business Summary

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Number of employees: 201

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Therapeutics
100.0 %
42 100.0 % 44 100.0 % +5.68%

Sales per region

USD in Million2022Weight2023Weight Delta
Netherlands
100.0 %
42 100.0 % 44 100.0 % +5.68%

Managers

Managers TitleAgeSince
Bill Lundberg CEO
 Chief Executive Officer 60 19-06-11
Gregory Perry DFI
 Director of Finance/CFO 63 16-04-30
Ernesto Wasserman CTO
 Chief Tech/Sci/R&D Officer - 16-11-30
Cecilia Anna Wilhelmina Geuijen CTO
 Chief Tech/Sci/R&D Officer 56 21-04-30
Andrew Joe CTO
 Chief Tech/Sci/R&D Officer 58 20-07-26
Peter Silverman COO
 Chief Operating Officer 46 17-01-31
John de Kruif CTO
 Chief Tech/Sci/R&D Officer 60 07-03-31
Sherri L. Spear IRC
 Investor Relations Contact - -
Ashley Pereira LAW
 General Counsel - 21-08-31
Shannon Campbell PRN
 Corporate Officer/Principal - 22-01-31

Members of the board

Members of the board TitleAgeSince
Gregory Perry DFI
 Director of Finance/CFO 63 16-04-30
Maxine Gowen BRD
 Director/Board Member 66 21-05-27
Paolo Pucci BRD
 Director/Board Member 63 20-06-29
Anand Mehra CHM
 Chairman 48 15-08-25
Mark Iwicki BRD
 Director/Board Member 57 15-04-30
Bill Lundberg CEO
 Chief Executive Officer 60 19-06-11
Victor Sandor BRD
 Director/Board Member 57 19-06-11
Len Kanavy BRD
 Director/Board Member 62 18-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 58,687,551 54,301,344 ( 92.53 %) 0 92.53 %

Shareholders

NameEquities%Valuation
Commodore Capital LP
8.202 %
4,747,373 8.202 % 214 M $
INCYTE CORPORATION
6.919 %
4,004,544 6.919 % 180 M $
Federated Global Investment Management Corp.
6.284 %
3,637,309 6.284 % 164 M $
Samlyn Capital LLC
5.896 %
3,412,410 5.896 % 154 M $
Deerfield Management Co. LP (Private Equity)
5.218 %
3,019,901 5.218 % 136 M $
BVF, Inc.
4.756 %
2,752,420 4.756 % 124 M $
RTW Investments LP
4.101 %
2,373,625 4.101 % 107 M $
Federated Global Investment Management Corp.
3.970 %
2,297,700 3.970 % 103 M $
Venrock Associates
3.712 %
2,148,214 3.712 % 97 M $
Wellington Management Co. LLP
3.472 %
2,009,403 3.472 % 90 M $

Company contact information

Merus NV

Uppsalalaan 17 3rd-4th Floor

3584 CM, Utrecht

+31 30 253 8800

http://www.merus.nl
address Merus N.V.(MRUS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Merus N.V.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
41.97 USD
Average target price
60.45 USD
Spread / Average Target
+44.04%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MERUS N.V. Stock Merus N.V.
+52.62% 2.46B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.86% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.49% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MRUS Stock
  4. Company Merus N.V.